Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of IBI3011 for acute gouty arthritis flare
CTR20263509Phase 2Active
- Sponsor
- InnoCare Pharma
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of IBI3011 in acute gout flare, sponsored by InnoCare Pharma. Started Sep 2026; status: active.
02
Drugs
IBI3011
03
Conditions
acute gout flare
Beyond the preview
Go deeper on CTR20263509.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263509.